BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
March 16, 2023 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia-Final-Logo-2016-JPEG.jpg
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
March 06, 2023 07:00 ET | BioCardia, Inc.
New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
February 01, 2023 06:30 ET | BioCardia, Inc.
SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Letter to Shareholders
December 22, 2022 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces $3.6 Million Private Placement of Common Stock
December 15, 2022 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
November 09, 2022 16:05 ET | BioCardia, Inc.
SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
November 02, 2022 17:31 ET | BioCardia, Inc.
SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting
October 03, 2022 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia-Final-Logo-2016-JPEG.jpg
CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting
September 14, 2022 07:00 ET | BioCardia, Inc.
Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
September 09, 2022 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment...